PREVENTION OF BONE MINERAL LOSS IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES
Journal
Македонски медицински преглед=Macedonian Medical Review
Date Issued
2020
Author(s)
Filip Guchev
Mimoza Nicolovska-Kotevska
Dubravka Antova
Baskim Osmani
Abstract
Introduction. Corticosteroids are therapeutic support
for many medical conditions including systemic inflammatory rheumatic diseases. Secondary osteoporosis
is one of the major complications from this therapy.
Bisphosphonates are indicated for prevention and treatment of corticosteroid-induced osteoporosis.
Aim. In a retrospective cross-sectional study to assess
the effect of the early use of bisphosphonates on bone
mineral density in patients with inflammatory rheumatic
diseases treated with corticosteroids.
Methods. We compared bone mineral density in an
examined group of 75 posmenopausal women with inflammatory rheumatic diseases on a corticosteroid therapy who were treated early with bisphosphonates, with
a control group of 80 postmenopausal women with
osteoarthritis who have never been treated with corticosteroids. Bone mineral density was measured at the
lumbar spine and left femur using Dual X-Ray absorptimetry in both groups of subjects.
Results. Patients with inflammatory rheumatic diseases
had an average T-score at the lumbar spine of -2.19,
and -1.41 at the left hip. The average T-score for the control group was -2.24 at the lumbar spine and -1.53 at
the hip. Difference in T-score at the lumbar spine and the
left hip between the two groups was 0.073 and 0.300
(P=0.639 and P=0.048), respectively. There was no statistically significant difference in the T-scores for both groups.
Conclusion. Osteoporosis is more prevalent in patients
with inlammatory rheumatic diseases, both at the hips
and the spine. The early use of bisphosphonates in patients
with inflammatory rheumatic diseases, especially in those
who are on corticosteroids, can prevent the loss of
bone mineral density
for many medical conditions including systemic inflammatory rheumatic diseases. Secondary osteoporosis
is one of the major complications from this therapy.
Bisphosphonates are indicated for prevention and treatment of corticosteroid-induced osteoporosis.
Aim. In a retrospective cross-sectional study to assess
the effect of the early use of bisphosphonates on bone
mineral density in patients with inflammatory rheumatic
diseases treated with corticosteroids.
Methods. We compared bone mineral density in an
examined group of 75 posmenopausal women with inflammatory rheumatic diseases on a corticosteroid therapy who were treated early with bisphosphonates, with
a control group of 80 postmenopausal women with
osteoarthritis who have never been treated with corticosteroids. Bone mineral density was measured at the
lumbar spine and left femur using Dual X-Ray absorptimetry in both groups of subjects.
Results. Patients with inflammatory rheumatic diseases
had an average T-score at the lumbar spine of -2.19,
and -1.41 at the left hip. The average T-score for the control group was -2.24 at the lumbar spine and -1.53 at
the hip. Difference in T-score at the lumbar spine and the
left hip between the two groups was 0.073 and 0.300
(P=0.639 and P=0.048), respectively. There was no statistically significant difference in the T-scores for both groups.
Conclusion. Osteoporosis is more prevalent in patients
with inlammatory rheumatic diseases, both at the hips
and the spine. The early use of bisphosphonates in patients
with inflammatory rheumatic diseases, especially in those
who are on corticosteroids, can prevent the loss of
bone mineral density
File(s)![Thumbnail Image]()
Loading...
Name
Мак. мед. преглед 2020; 74 (2).pdf
Size
3.47 MB
Format
Adobe PDF
Checksum
(MD5):80d295d90eca059a18d24ad69322cde4